Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13455618 | 0.98 | NAMPT (0.67) | NAMPTNPC1GAARAB9ALMNA | |
| SCHEMBL3217000 | 0.90 | NAMPT (0.59) | NAMPTNPC1GAARAB9ALMNA | |
| SCHEMBL14627248 | 0.89 | NAMPT (0.68) | NAMPTNPC1GAARAB9ALMNA | |
| SCHEMBL3208598 | 0.86 | POLB (0.70) | NAMPTNPC1GAARAB9ALMNA | |
| SCHEMBL774990 | 0.84 | KCNQ3 (0.59) | NAMPTNPC1GAARAB9ALMNA | |
| SCHEMBL774842 | 0.83 | KMT2A (0.60) | NAMPTNPC1GAARAB9ALMNA | |
| SCHEMBL774698 | 0.83 | KCNQ3 (0.77) | — | |
| SCHEMBL5214172 | 0.82 | CSF1R (0.83) | NAMPTNPC1RAB9ALMNACSF1R | |
| SCHEMBL774620 | 0.81 | KCNQ3 (0.59) | LMNAABL1KDM4EMAPT | |
| SCHEMBL775233 | 0.81 | ROCK2 (0.65) | NAMPTNPC1RAB9ALMNAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | NAMPT 1742/4885NPC1 2916/4885GAA 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.